{
    "clinical_study": {
        "@rank": "153274", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if treatment with an anti-HIV drug containing\n      ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who\n      have failed an anti-HIV drug treatment containing nelfinavir."
        }, 
        "brief_title": "Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "HIV-infected patients will be treated with a ritonavir-enhanced Agenerase regimen."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients may be eligible for this study if they:\n\n          -  Are 18 years of age or older.\n\n          -  Are HIV-positive.\n\n          -  Have a viral load (level of HIV in the body) of more than 1,000 copies/ml.\n\n          -  Have had more than 12 weeks of prior anti-HIV drug treatment.\n\n          -  Have failed a previous anti-HIV treatment containing nelfinavir as the only protease\n             inhibitor.\n\n          -  Are responsive to Agenerase.\n\n          -  Are able to follow study requirements.\n\n        Exclusion Criteria\n\n        Patients will not be eligible for this study if they:\n\n          -  Are intolerant to ritonavir (an anti-HIV drug).\n\n          -  Have or have had problems with absorption.\n\n          -  Have liver disease or damage.\n\n          -  Have pancreatic disease or damage.\n\n          -  Have taken any protease inhibitor other than nelfinavir.\n\n          -  Are receiving investigational drugs or devices from another study.\n\n          -  Are pregnant or breast-feeding.\n\n          -  Currently use triazolam, astemizole, ergot medications, cisapride, midazolam,\n             bepridil, rifampin, terfenadine, or pimozide.\n\n          -  Have a  bleeding disorder.\n\n          -  Have previously been treated with Agenerase.\n\n          -  Are receiving nonnucleosides."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "December 1, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006591", 
            "org_study_id": "313A", 
            "secondary_id": "APV-430"
        }, 
        "intervention": [
            {
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Amprenavir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Ritonavir", 
                "Amprenavir"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "Ritonavir", 
            "VX 478", 
            "Salvage Therapy", 
            "Anti-HIV Agents", 
            "Drug Monitoring", 
            "Nelfinavir", 
            "Treatment Experienced"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77004"
                }, 
                "name": "Gathe, Joseph, M.D."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "The Safety and Efficacy of a Ritonavir-Enhanced Agenerase Regimen as Salvage Therapy in HIV-Infected Individuals", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006591"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gathe, Joseph, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2004"
    }, 
    "geocoordinates": {
        "Gathe, Joseph, M.D.": "29.76 -95.369"
    }
}